Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924389 · ClinicalTrials.gov registry record · Phase 4
Dolutegravir in Reservoirs
A Phase 4 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT02924389 is a Phase 4 study that was terminated before completion, run by Emory University. The registered enrollment target is 22 participants.
The verdict
NCT02924389, a Phase 4 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to find out how well the HIV medication dolutegravir gets into different parts of the body including blood plasma, special blood cells, and rectal tissue. Specifically, investigators want to compare how fast dolutegravir lowers the HIV viral load in these three different sites. In addition, as an exploratory aim, investigators seek to learn if there are any differences in how dolutegravir acts in males and females. Results of this study will provide more information about HIV medications and their limitations. In the future, this could help create better HIV medications that can get into these hard-to-reach places and eventually cure HIV infection.
Interventions
- DRUG Truvada
- DRUG dolutegravir
- DRUG Triumeq
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-09 |
| Est. Completion | 2019-09-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02924389
The ClinicalTrials.gov registry entry for NCT02924389 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Truvada is the first listed.
NCT02924389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02924389 about?
NCT02924389 is a clinical study titled "Dolutegravir in Reservoirs". The purpose of this study is to find out how well the HIV medication dolutegravir gets into different parts of the body including blood plasma, special blood cells, and rectal tissue. Specifically, investigators want to compare how fast dolutegravir lowers the HIV viral load in these three different...
What is the current status of trial NCT02924389?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2016-09. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT02924389?
The interventions under investigation include: Truvada (DRUG), dolutegravir (DRUG), Triumeq (DRUG).
Who is sponsoring clinical trial NCT02924389?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.